These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4323972)

  • 21. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of myasthenia with corticotropic hormones].
    Goulon M; Barois A; Gajdos P; Grosbuis S; Joron MH; Bennaiche M
    Sem Hop; 1972 Dec; 48(51):3371-5. PubMed ID: 4347494
    [No Abstract]   [Full Text] [Related]  

  • 23. Results with ACTH and spironolactone in severe cases of myasthenia gravis.
    von Reis G; Liljestrand A; Matell G
    Acta Neurol Scand Suppl; 1965; 13 Pt 2():463-71. PubMed ID: 4284453
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of subacute administration of discrete doses of ACTH in medium grade myasthenia. (Serial electromyographic study)].
    Pinelli P
    Riv Neurol; 1967; 37(4):343-65. PubMed ID: 4295653
    [No Abstract]   [Full Text] [Related]  

  • 25. Myasthenia gravis and myasthenic syndromes treated with prednisone.
    Kjaer M
    Acta Neurol Scand; 1971; 47(4):464-74. PubMed ID: 4330810
    [No Abstract]   [Full Text] [Related]  

  • 26. Corticosteroids and corticotrophin in the treatment of neurologic disorders, with emphasis on neurologic disorders of childhood.
    Chutorian AM
    Clin Neuropharmacol; 1982; 5(3):239-65. PubMed ID: 6288235
    [No Abstract]   [Full Text] [Related]  

  • 27. Thymectomy in the treatment of ocular myasthenia gravis.
    Roberts PF; Venuta F; Rendina E; De Giacomo T; Coloni GF; Follette DM; Richman DP; Benfield JR
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):562-8. PubMed ID: 11547310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Orbicularis oculi electromyogram in a girl with ocular myasthenia gravis].
    Ichiyama T; Kimoto J; Hayashi T; Tanaka H
    No To Hattatsu; 1992 Jul; 24(4):380-3. PubMed ID: 1520516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myasthenia gravis, ulcerative colitis and lichen planus.
    Miller TN
    Proc R Soc Med; 1971 Aug; 64(8):807-8. PubMed ID: 4328085
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment with ACTH in the myasthenic syndrome with an immunological substratum].
    Radu H; Roşu AM; Lenkei R; Ionescu V; Darko Z
    Neurol Psihiatr Neurochir; 1973; 18(4):377-84. PubMed ID: 4356514
    [No Abstract]   [Full Text] [Related]  

  • 31. [On the relationship between negative effects and positive effects of ACTH therapy in myasthenic patients].
    Pinelli P; Gandiglio G
    Riv Neurol; 1968; 38(2):77-84. PubMed ID: 4298338
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of polstigmine on the status of the respiratory muscles and pulmonary function in patients with myasthenia gravis].
    Radwan L; Strugalska MH; Koziorowski A
    Pneumonol Pol; 1987; 55(11-12):499-503. PubMed ID: 3444736
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapy of myasthenia (author's transl)].
    Birnberger KL; Struppler A
    MMW Munch Med Wochenschr; 1976 Dec; 118(51):1653-6. PubMed ID: 187931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternate-dy prednisone in a patient with myasthenia gravis.
    Warmolts JR; Engel WK; Whitaker JN
    Lancet; 1970 Dec; 2(7684):1198-9. PubMed ID: 4098476
    [No Abstract]   [Full Text] [Related]  

  • 35. Corticotropin therapy in myasthenia gravis: indications and limitations.
    Namba T; Shapiro MS; Brunner NG; Grob D
    Neurology; 1970 Apr; 20(4):385. PubMed ID: 4327339
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of long-acting synthetic corticotrophin in hypersensitive asthmatics and normal subjects.
    el-Shaboury AH
    Br Med J; 1968 Sep; 3(5619):653-5. PubMed ID: 4299775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of myasthenia with adrencorticotrophins (ACTH and Synacthen). Apropos of 100 treatments in 25 patients].
    Goulon M; Nouailhat F; Barois A; Grosbuis S; Joron MH
    Rev Neurol (Paris); 1972 Oct; 127(4):457-70. PubMed ID: 4355521
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.
    Fasano A; Bentivoglio AR; Ialongo T; Soleti F; Evoli A
    Neurology; 2005 Jun; 64(12):2155-6. PubMed ID: 15985599
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Benatar M; Kaminski HJ;
    Neurology; 2007 Jun; 68(24):2144-9. PubMed ID: 17460154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.